North America Biguanide Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

North American Biguanide Market is segmented into geography (United States, Canada, and the rest of North America).

North American Biguanide Market Size

North America Biguanide Market Summary
View Global Report

North American Biguanide Market Analysis

The North America Biguanide Market size is estimated at USD 1.40 billion in 2025, and is expected to reach USD 1.59 billion by 2030, at a CAGR of 2.59% during the forecast period (2025-2030).

The COVID-19 pandemic positively impacted the North American Biguanide Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.

Biguanides are a class of medications used to treat type 2 diabetes. They work by reducing the production of glucose that occurs during digestion. Metformin is the only biguanide currently available in most countries for treating diabetes. Glucophage (metformin) and Glucophage XR (metformin extended release) are well-known brand names for these drugs. Others include Fortamet, Glumetza, and Riomet. Metformin is also available in combination with several other types of diabetes medications, such as sulfonylureas.

As Type 2 diabetes is associated with both poorer clinical outcomes during the COVID-19 pandemic and an increased risk of death in such hospitalized patients, the role of glucose control has been emphasized to improve the prognosis. Metformin is the first-line choice for the management of hyperglycemia in T2DM. Besides being an important glucose-lowering agent, metformin also has significant anti-inflammatory. Therefore, metformin has been a potential candidate for treating patients affected by COVID-19 infection, with type 2 diabetes, as well as an excellent antidiabetic (glucose-lowering) agent during COVID-19 pandemic times.

In North America, till April 2022, the United States is having the highest COVID cases around 82 million, the country also registered the highest death rate. According to the Diabetes Voice article published in May 2020, close to 40,000 deaths of people who are having diabetes. Pandemic emergency has created a rise in remote care from both patients and providers and removed many long-standing regulatory barriers.

The North American region had witnessed an alarming increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates by monitoring their blood glucose levels.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

North American Biguanide Industry Overview

The North American Biguanidemarket is fragmented, with manufacturers like Takeda, Merck, Sanofi, GlaxoSmithKline, Bristol-Myers Squibb, and Boehringer Ingelheim Pharmaceuticals having a global market presence. The market is highly competitive due to generic drug manufacturers' presence.

North American Biguanide Market Leaders

  1. Sanofi Aventis

  2. Bristol-Myers Squibb

  3. Glenmark Pharmaceuticals

  4. Takeda Pharmaceuticals

  5. Merck & Co., Inc.

  6. *Disclaimer: Major Players sorted in no particular order
North America Biguanide Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

North American Biguanide Market News

  • February 2023: Zydus Lifesciences Limited received tentative approval from the USFDA for Invokamet tablets (canagliflozin and metformin hydrochloride combination). Canagliflozin and metformin combination products are indicated as an adjunct to diet and exercise. It is to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing metformin or canagliflozin. It is also used in patients already treated with canagliflozin and metformin.
  • July 2022: Zydus Lifesciences announced that it had received final approval from the USFDA to market Empagliflozin and Metformin Hydrochloride tablets in multiple strengths. Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. They are also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.

North American Biguanide Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Biguanide
  • 5.2 Geography
    • 5.2.1 United States
    • 5.2.2 Canada
    • 5.2.3 Rest of North America

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Merck
    • 7.1.2 Takeda
    • 7.1.3 GlaxoSmithKline
    • 7.1.4 Sanofi
    • 7.1.5 Boehringer Ingelheim Pharmaceuticals
    • 7.1.6 Glenmark
    • 7.1.7 Bristol-Myers Squibb
    • 7.1.8 Zydus Cadila
  • *List Not Exhaustive
  • 7.2 Company Share Analysis
    • 7.2.1 Merck
    • 7.2.2 Takeda
    • 7.2.3 Sanofi
    • 7.2.4 Others

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*The report covers a segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

North American Biguanide Industry Segmentation

Biguanides are a class of diabetes medications used for people with type 2 diabetes. The North American Biguanide Market is segmented into geography (United States, Canada, and the rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.

Geography United States
Canada
Rest of North America
Need A Different Region or Segment?
Customize Now

North American Biguanide Market Research FAQs

How big is the North America Biguanide Market?

The North America Biguanide Market size is expected to reach USD 1.40 billion in 2025 and grow at a CAGR of 2.59% to reach USD 1.59 billion by 2030.

What is the current North America Biguanide Market size?

In 2025, the North America Biguanide Market size is expected to reach USD 1.40 billion.

Who are the key players in North America Biguanide Market?

Sanofi Aventis, Bristol-Myers Squibb, Glenmark Pharmaceuticals, Takeda Pharmaceuticals and Merck & Co., Inc. are the major companies operating in the North America Biguanide Market.

What years does this North America Biguanide Market cover, and what was the market size in 2024?

In 2024, the North America Biguanide Market size was estimated at USD 1.36 billion. The report covers the North America Biguanide Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the North America Biguanide Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

North America Biguanide Industry Report

Statistics for the 2025 North America Biguanide market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. North America Biguanide analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

North America Biguanide Market Report Snapshots

Compare market size and growth of North America Biguanide Market with other markets in Healthcare Industry

North America Biguanide Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)